Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles.

Journal Article (Journal Article)

Vascular anomalies, including local and peripheral thrombosis, are a hallmark of glioblastoma (GBM) and an aftermath of deregulation of the cancer cell genome and epigenome. Although the molecular effectors of these changes are poorly understood, the upregulation of podoplanin (PDPN) by cancer cells has recently been linked to an increased risk for venous thromboembolism (VTE) in GBM patients. Therefore, regulation of this platelet-activating protein by transforming events in cancer cells is of considerable interest. We used single-cell and bulk transcriptome data mining, as well as cellular and xenograft models in mice, to analyze the nature of cells expressing PDPN, as well as their impact on the activation of the coagulation system and platelets. We report that PDPN is expressed by distinct (mesenchymal) GBM cell subpopulations and downregulated by oncogenic mutations of EGFR and IDH1 genes, along with changes in chromatin modifications (enhancer of zeste homolog 2) and DNA methylation. Glioma cells exteriorize their PDPN and/or tissue factor (TF) as cargo of exosome-like extracellular vesicles (EVs) shed from cells in vitro and in vivo. Injection of glioma-derived podoplanin carrying extracelluar vesicles (PDPN-EVs) activates platelets, whereas tissue factor carrying extracellular vesicles (TF-EVs) activate the clotting cascade. Similarly, an increase in platelet activation (platelet factor 4) or coagulation (D-dimer) markers occurs in mice harboring the corresponding glioma xenografts expressing PDPN or TF, respectively. Coexpression of PDPN and TF by GBM cells cooperatively affects tumor microthrombosis. Thus, in GBM, distinct cellular subsets drive multiple facets of cancer-associated thrombosis and may represent targets for phenotype- and cell type-based diagnosis and antithrombotic intervention.

Full Text

Duke Authors

Cited Authors

  • Tawil, N; Bassawon, R; Meehan, B; Nehme, A; Montermini, L; Gayden, T; De Jay, N; Spinelli, C; Chennakrishnaiah, S; Choi, D; Adnani, L; Zeinieh, M; Jabado, N; Kleinman, CL; Witcher, M; Riazalhosseini, Y; Key, NS; Schiff, D; Grover, SP; Mackman, N; Couturier, CP; Petrecca, K; Suvà, ML; Patel, A; Tirosh, I; Najafabadi, H; Rak, J

Published Date

  • March 23, 2021

Published In

  • Blood Adv

Volume / Issue

  • 5 / 6

Start / End Page

  • 1682 - 1694

PubMed ID

  • 33720339

Pubmed Central ID

  • PMC7993100

Electronic International Standard Serial Number (EISSN)

  • 2473-9537

Digital Object Identifier (DOI)

  • 10.1182/bloodadvances.2020002998


  • eng

Conference Location

  • United States